Abstract
In recent years, anti-PD(L)-1 ICIs have been adopted in the first-line (1L) Tx of aNSCLC in EU4 (France, Germany, Italy, Spain) and UK. There is limited information about actual regimens used in the real-world setting. This study evaluated Tx characteristics in aNSCLC patients without actionable mutations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
